Ergéa Group appoints Dr. Michael Thorwarth as Group CEO; Dr. Guglielmo Brayda di Soleto transitions to Co-Chairman of Ergéa Group.
As of September 16th 2024, Dr. Michael Thorwarth, currently CEO of Ergéa Deutschland, has been appointed as the new Group CEO. He will continue and expand Ergéa’s collaborative leadership model and work in partnership with Michele Corti, CEO of Medipass|Ergéa Group, and David Rolfe, CEO of Ergéa UK and Ireland, to drive and sustain Ergéa Group’s ongoing growth and success.
As part of this leadership transition, the founding doctor of Ergéa Group and Medipass Spa, Dr. Guglielmo Brayda di Soleto, will assume the role of Co-Chairman on Ergéa Group’s Board of Directors. Collaborating with the other chairmen, group management, and regional executives, he will contribute to refining and implementing the long-term business plan, as well as further enhancing the medical and operational excellence across the whole group. He will also continue to lead Ergéa Group’s Scientific Medical Committee and continue to support expansion of the group to new geographical markets.
Under Dr. Brayda di Soleto’s leadership, Ergéa Group has achieved significant geographical expansion, evolving into a large Pan-European player with key acquisitions in countries such as Germany and the UK. This expansion has solidified Ergéa Group’s position as the leading European provider of managed and clinical solutions in advanced medical technologies for oncology. Dr. Brayda di Soleto’s guidance has also set the group on a path towards greater integration, with a focus on unifying knowledge and management practices across the countries to create a truly cohesive group. This period of growth has also included major transformations, such as the establishment of centralised functions, rebranding initiatives, the implementation of group-wide policies and procedures, and improvements in quality and decision-making through relevant governing committees.
As I reflect on the journey since establishing our founding business in Italy three decades ago, I feel a deep sense of appreciation for all we have achieved. The true measure of a healthcare company’s value lies in the positive impact it has on the communities and patients it serves. Today, Ergéa Group stands as a strong and growing platform that enhances the lives of millions of patients across Europe by improving their access to high-quality diagnostics and care. I am confident that Dr. Thorwarth, with his dual expertise as a medical doctor and business strategist, and in close collaboration with our country CEOs, is well-equipped to build on our strong foundation and continue driving Ergéa Group’s growth and success.
Dr. Guglielmo Brayda di Soleto
Dr. Thorwarth has studied medicine and dentistry, specialising in maxillofacial and plastic surgery. After nearly a decade of clinical experience at two university hospitals, he expanded his experience by completing an MBA in Healthcare Management, which facilitated his transition into business consulting. Over the course of almost ten years at Boston Consulting Group, he advised Medtech companies and private equity clients, eventually advancing to the role of Managing Director & Partner. In 2019, he took the CEO role of Dein Dental, where he successfully established a network of ~40 dental care centres across Germany. Dr. Thorwarth joined Ergéa Deutschland as CEO in 2023.
I am honored to lead the Ergéa Group together with Michele Corti, and David Rolfe, building upon the outstanding legacy left by Dr. Brayda di Soleto. As we move forward, our focus will be on continuing our journey towards greater integration, fostering collaboration, cross-fertilising service models and driving transformations that support both our direct patient care and our partnerships with private and public hospitals.
Dr. Michael Thorwarth
We extend our appreciation to Dr. Brayda di Soleto for his remarkable contributions as Group CEO and congratulate Dr. Thorwarth on his new role.